XILIO THERAPEUTICS INC's ticker is and the CUSIP is 98422T100. A total of 43 filers reported holding XILIO THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,878,645 | -19.5% | 890,353 | 0.0% | 0.00% | – |
Q2 2023 | $2,332,725 | -17.4% | 890,353 | 0.0% | 0.00% | – |
Q1 2023 | $2,822,419 | +17.8% | 890,353 | 0.0% | 0.00% | – |
Q4 2022 | $2,395,049 | -7.7% | 890,353 | -0.1% | 0.00% | – |
Q3 2022 | $2,595,000 | +112.0% | 891,533 | +112.7% | 0.00% | – |
Q2 2022 | $1,224,000 | -58.4% | 419,165 | +0.7% | 0.00% | – |
Q1 2022 | $2,944,000 | -56.6% | 416,393 | -1.8% | 0.00% | – |
Q4 2021 | $6,788,000 | – | 424,224 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RiverVest Venture Management LLC | 1,441,444 | $3,041,447 | 7.52% |
Trustees of Columbia University in the City of New York | 249,635 | $526,730 | 0.97% |
Atlas Venture Life Science Advisors, LLC | 2,759,344 | $5,822,216 | 0.90% |
Octagon Capital Advisors LP | 2,318,500 | $4,892,035 | 0.75% |
Bain Capital Life Sciences Investors, LLC | 2,805,413 | $5,919,421 | 0.66% |
HARVARD MANAGEMENT CO INC | 416,059 | $878 | 0.10% |
Rock Springs Capital Management LP | 1,440,759 | $3,040,001 | 0.08% |
Soleus Capital Management, L.P. | 226,941 | $478,846 | 0.04% |
Artal Group S.A. | 450,000 | $950 | 0.04% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 110,481 | $233,115 | 0.01% |